Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) Non Operating Income: 2022-2025

Historic Non Operating Income for Praxis Precision Medicines (PRAX) over the last 4 years, with Sep 2025 value amounting to $4.4 million.

  • Praxis Precision Medicines' Non Operating Income fell 10.15% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year increase of 54.45%. This contributed to the annual value of $17.3 million for FY2024, which is 460.27% up from last year.
  • Latest data reveals that Praxis Precision Medicines reported Non Operating Income of $4.4 million as of Q3 2025, which was down 10.43% from $4.9 million recorded in Q2 2025.
  • Praxis Precision Medicines' Non Operating Income's 5-year high stood at $5.4 million during Q1 2025, with a 5-year trough of $132,000 in Q1 2022.
  • For the 3-year period, Praxis Precision Medicines' Non Operating Income averaged around $3.2 million, with its median value being $4.4 million (2025).
  • In the last 5 years, Praxis Precision Medicines' Non Operating Income spiked by 642.44% in 2024 and then dropped by 10.15% in 2025.
  • Over the past 4 years, Praxis Precision Medicines' Non Operating Income (Quarterly) stood at $280,000 in 2022, then surged by 231.43% to $928,000 in 2023, then spiked by 468.64% to $5.3 million in 2024, then decreased by 10.15% to $4.4 million in 2025.
  • Its Non Operating Income stands at $4.4 million for Q3 2025, versus $4.9 million for Q2 2025 and $5.4 million for Q1 2025.